Opendata, web and dolomites

TheraPD TERMINATED

TheraPD: Smart and safer automated peritoneal dialysis by means of sterile connectivity, bio-sensors control systems and more biocompatible solutions for preventing rapid degradation of peritoneal mem

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TheraPD project word cloud

Explore the words cloud of the TheraPD project. It provides you a very rough idea of what is the project "TheraPD" about.

65    special    7m    renal    comfort    solid    patients    individual    glucose    safe    causing    peritonitis    avoids    cycler    3h    profit    automated    cells    healthcare    market    innovative    solving    week    dropout    dialysis    drawbacks    ec    patient    peritoneal    either    risk    world    frequency    home    prescription    outcome    spending    date    therapy    ultrafiltration    worldwide    rapid    biosensors    kidney    undergo    equipped    body    million    35    launch    dialysate    transplants    doubled    clinical    treatment    11    overfilling    reduce    people    biosensing    earning    solutions    generating    irreversible    budgets    transplant    eligible    mesothelium    esrd    benefits       ph    least    zero    stage    biocompatible    prevents    poorly    solution    previously    monitor    europeans    penetrating    expanding    capacity    roi    haemodialysis    innovation    cavity    entails    demonstrated    15    customize    connector    efficient    renders    nhs    safety    almost    pd    degradation    concentration    disease       hospital    times    consist    significantly    machine    therapd    connected    sterile    unmet    societal    membrane    250   

Project "TheraPD" data sheet

The following table provides information about the project.

Coordinator
GLOMERIA THERAPEUTICS SOCIETA' A RESPONSABILITA' LIMITATA 

Organization address
address: VIA PADRE UGOLINO FRASCA, SNC
city: CHIETI
postcode: 66100
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website https://youtu.be/YGVClIl33qs
 Total cost 2˙838˙126 €
 EC max contribution 2˙838˙126 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2016
 Duration (year-month-day) from 2016-10-01   to  2019-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GLOMERIA THERAPEUTICS SOCIETA' A RESPONSABILITA' LIMITATA IT (CHIETI) coordinator 2˙838˙126.00

Map

 Project objective

2.7 million People worldwide (250,000 Europeans) have kidney transplants or undergo a dialysis treatment because of irreversible end-stage renal disease (ESRD). This number has more than doubled over the past 15 years and involves 3-5% of NHS budgets. Current therapy consist in either a kidney transplant, haemodialysis connected to a machine at the hospital for at least 3h, 3 times a week, or the better-outcome cost-effective home-based peritoneal dialysis (PD). Although widely demonstrated to have greater results and to be cost-effective, PD is only used in 11% of the cases because of its drawbacks: peritonitis (35% dropout), poorly biocompatible solutions available, and overfilling of the peritoneal cavity causing rapid degradation on the mesothelium membrane. Our innovative TheraPD solution provide the most safe and efficient automated peritoneal dialysis therapy to date. It entails a comprehensive system composed by a sterile connector (renders peritonitis risk almost zero), a biosensing control system (avoids overfilling), and a new biocompatible dialysate which prevents degradation of peritoneal membrane cells. Another innovation is that our cycler will be equipped with special biosensors to measure the concentration of glucose and pH, this allows to customize the dialysis prescription according to the ultrafiltration capacity of the patient, increases safety level of the treatment and it allows to monitor the uptake of glucose by the patient. By solving these unmet clinical needs, we will increase PD usage by expanding it to people who were not previously eligible, reduce treatment frequency or duration, customize the dialysis treatment according to the response of the patient’s body, increase patients’ comfort and significantly reduce healthcare spending. With EC’s support we will achieve all these societal and individual benefits while earning €4.7M profit, penetrating 1.15% of the world market, and generating a solid ROI of 1.65 after 5 years from launch.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THERAPD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "THERAPD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More